Feb 2011 $8 M No. 3 $2 to $10 million 41
ImmunoCellular Therapeutics, Ltd.: Raise no. 3, Feb 2011 × Investors in this round 41 investors had bought by the notice of Mar 11, 2011: 41 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them, other: Unit consisting of 1 share of common stock and warrant for .5 share of common stock.
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $566,345
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice C. Kirk Peacock · Executive Officer James Kirk Bender · Executive Officer Manish Singh · Executive Officer, Director Jacqueline Kirk Brandwynne · Director John S. Yu · Director Navdeep A. Jaikaria · Director Rahul A. Singhvi · Director Richard A. Cowell · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Summer Street Research Partners (CRD 127142) · Boston, Massachusetts Sold in AL, AZ, CA, CO, CT, IL, MA, NJ, NY, PA, TN, TX Dawson James Securities, Inc. (CRD 130645) · Boca Raton, Florida Sold in AL, AZ, CA, CO, CT, IL, MA, NJ, NY, PA, TN, TX Remarks in the notice On fees: “Sales commission consisted of $566,345 and 5 year warrants to purchase aggregate of 208,791 shares of common stock at exercise price of $2.25.”On the use of proceeds: “All of the proceeds are being added to issuer's working capital which may in the future be used to pay salaries and fees of officers and directors.”Signed by C. Kirk Peacock, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 11, 2011. Read the notice at the SEC .
equity SEC May 2010 $3 M No. 2 $2 to $10 million 12
ImmunoCellular Therapeutics, Ltd.: Raise no. 2, May 2010 × Investors in this round 12 investors had bought by the notice of Jun 3, 2010: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them, other: Sold in units with each unit consisting of 1 share of common stock and warrant for .5 share of common stock.
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $46,550
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice C. Kirk Peacock · Executive Officer James Kirk Bender · Executive Officer Manish Singh · Executive Officer, Director Jacqueline Kirk Brandwynne · Director John L. Yu · Director Navdeep A. Jaikaria · Director Richard A. Cowell · Director Robert L. Martuza · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Gilford Securities Incorporated (CRD 8076) · New York, New York Sold in NY Remarks in the notice On fees: “Sales commission consisted of $46,550 and 36-month warrant to purchase 42,318 shares of common stock at exercise price of $1.50 per share.”On the use of proceeds: “All of the proceeds are being added to issuer's working capital which may in the future be used to pay salaries and fees of officers and directors.”Signed by Manish Singh, Ph.D., President & CEO. Source: SEC Form D, newest notice filed Jun 3, 2010. Read the notice at the SEC .
equity SEC Mar 2010 $2 M No. 1 Under $2 million 18
ImmunoCellular Therapeutics, Ltd.: Raise no. 1, Mar 2010 × Investors in this round 18 investors had bought by the notice of Apr 13, 2010: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them, other: Sold in units with each unit consisting of 1 share of common stock and warrant for .4 share of common stock.
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $34,800
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice C. Kirk Peacock · Executive Officer James Kirk Bender · Executive Officer Manish Singh · Executive Officer, Director Jacqueline Kirk Brandwynne · Director John L. Yu · Director Navdeep A. Jaikaria · Director Richard A. Cowell · Director Robert L. Martuza · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Scarsdale Equities LLC (CRD 134602) · New York, New York Sold in NY Remarks in the notice On fees: “Sales commission consisted of $34,800 and 26-month warrant to purchase 104,400 shares of common stock at exercise price of $1.15 per share.”Signed by Manish Singh, Ph.D., President & CEO. Source: SEC Form D, newest notice filed Apr 13, 2010. Read the notice at the SEC .
equity SEC